PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Aptabio is approaching key clinical readouts for isuzinaxib (APX-115) and APX-343A, yet revenue remains minimal and operating losses have continued every year.
Global Phase 2 topline data for the contrast-induced acute kidney injury (CI-AKI) candidate isuzinaxib are expected around late Q3 to early Q4 2026.
The immuno-oncology candidate APX-343A has started first-patient dosing in a Keytruda combination trial with MSD and disclosed monotherapy Phase 1 data at ASCO 2026.
In Q2 2026, net income attributable to owners turned positive despite a continuing operating loss, a divergence that appears to stem from non-operating factors.
Operating cash flow was negative every year from 2022 through 2025, and shareholders' equity has trended lower over the same period.
The debt ratio declined from 42.9% in 2024 to 27.2% in 2025, but the company still must fund clinical costs without a meaningful revenue base.
Aptabio is a clinical-stage biotech pursuing first-in-class drug development around three platform technologies: NOX (NADPH oxidase) inhibition for oxidative stress control, cancer-associated fibroblast (CAF) modulation, and an aptamer-drug conjugate (Apta-DC) platform.
Its lead asset, isuzinaxib (APX-115), is being developed for both diabetic kidney disease (DKD) and contrast-induced acute kidney injury (CI-AKI), with a domestic Phase 2b trial in DKD and Phase 2 trials for CI-AKI running in both Korea and the United States.
The CAF-modulation-based immuno-oncology candidate APX-343A is in Phase 1 at three domestic institutions including Severance Hospital, with a separate arm combining it with MSD's Keytruda. The Apta-DC-based blood cancer candidate Apta-16 has received U.S.
FDA orphan drug designation and is being prepared for domestic Phase 1 entry in the second half of the year. The oral wet age-related macular degeneration candidate ABF-101 resumed its U.S. Phase 1 trial after a clinical hold was lifted.
Beyond these pipelines, the company generates modest revenue through a health-functional-food ODM business and a pet-care business, which together account for most of its reported sales given the absence of a commercialized drug.
On the competitive front, Swedish company Calliditas Therapeutics (formerly Genkyotex) developed setanaxib using the same NOX-inhibition mechanism, but that compound inhibited only NOX1 and NOX4 and failed to demonstrate efficacy in a Phase 2 trial for diabetic nephropathy. Aptabio positions its 'Pan-NOX' approach, which targets all seven NOX isoenzymes, as a key differentiator.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.1B | -₩4.1B | −368.5% |
| 2025Q3 | ₩1.2B | -₩3.4B | −283.3% |
| 2025Q4 | ₩1B | -₩5.7B | −569.3% |
| 2026Q1 | ₩1B | -₩6.1B | −636.6% |
| 2026Q2 | ₩1.6B | -₩3.6B | −223.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩48,352,850 | -₩9.5B | -₩10.6B | −19661.2% | −20.2% | 7.1% |
| 2023 | ₩300M | -₩16.4B | -₩12.1B | −5055.6% | −19.7% | 50.8% |
| 2024 | ₩3.4B | -₩18.9B | -₩29.4B | −561.0% | −54.2% | 42.9% |
| 2025 | ₩3.7B | -₩15.8B | -₩16.3B | −428.4% | −34.6% | 27.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22
Consolidated revenue for 2025 was KRW 3.698 billion, a modest increase from KRW 3.361 billion in 2024, while the operating loss narrowed to KRW 15.84 billion from KRW 18.85 billion, and the net loss attributable to owners shrank sharply to KRW 16.35 billion from KRW 29.38 billion in 2024.
Going further back, revenue was just KRW 48 million in 2022 and KRW 324 million in 2023 against operating losses of KRW 9.51 billion and KRW 16.37 billion respectively, underscoring that the company has essentially funded clinical spending without a meaningful revenue base.
On a quarterly basis, the operating loss narrowed to KRW 3.38 billion in Q3 2025 from KRW 4.14 billion in Q2 2025, then widened again to KRW 5.70 billion in Q4 2025 and KRW 6.10 billion in Q1 2026, the largest quarterly loss in the observed window.
In Q2 2026, revenue jumped to KRW 1.60 billion from KRW 0.96 billion the prior quarter and the operating loss narrowed to KRW 3.57 billion, while net income attributable to owners notably turned positive at KRW 1.12 billion.
This swing to positive net income amid a continuing operating loss appears to be driven by non-operating factors and should not be read as an immediate signal of improved core profitability.
Summing the most recent four quarters (Q3 2025 through Q2 2026), the net loss attributable to owners totals roughly KRW 14.87 billion, indicating losses remain substantial.
Operating cash flow was negative every year, at KRW -6.83 billion in 2022, KRW -14.10 billion in 2023, KRW -12.16 billion in 2024, and KRW -15.28 billion in 2025, and shareholders' equity fell from KRW 52.37 billion in 2022 to KRW 47.18 billion in 2025 as a result.
Total liabilities dropped sharply from KRW 23.24 billion in 2024 to KRW 12.84 billion in 2025, lowering the debt ratio from 42.9% to 27.2%; while favorable for balance-sheet health, this occurred alongside a decline in equity and should be viewed in that context.
The therapeutic areas Aptabio targets—diabetic kidney disease, contrast-induced acute kidney injury, immuno-oncology, and wet age-related macular degeneration—are all considered areas of significant unmet medical need with limited or no fundamental treatment options.
CI-AKI in particular has no approved therapy anywhere in the world, meaning a successful development could secure first-in-class status.
In the competitive landscape for NOX inhibition, Setanaxib, originating from France's Genkyotex and later held by Sweden's Calliditas Therapeutics, inhibited only NOX1 and NOX4 and failed to demonstrate efficacy in a Phase 2 trial for diabetic nephropathy.
Nevertheless, Calliditas was acquired by Japan's Asahi Kasei in May 2024 for approximately $1.1066 billion, a transaction often cited as evidence of large pharma interest in the NOX-inhibition mechanism itself.
In immuno-oncology, competition around combination regimens and next-generation mechanisms is intensifying ahead of patent expirations for blockbuster checkpoint inhibitors like Keytruda, placing APX-343A—backed by a collaboration agreement with MSD—within this broader trend.
The wet AMD market is seen as growing amid an aging population and the inconvenience of existing intravitreal injection therapies, creating demand for oral alternatives.
That said, Aptabio is developing multiple pipelines in parallel without an approved, revenue-generating product, which leaves it at a relative disadvantage in funding capacity and development speed compared with larger domestic and global pharmaceutical companies.
According to company statements, the global Phase 2 trial of isuzinaxib for CI-AKI completed dosing of its last patient and began a 12-week follow-up in April, with the company targeting topline data disclosure between late Q3 and early Q4 2026.
The domestic Phase 2b trial for the DKD indication involves approximately 186 patients, with enrollment more than 50% complete; the company's stated timeline calls for enrollment completion within the year, dosing completion in the first half of 2027, and results in the second half of 2027.
APX-343A disclosed monotherapy Phase 1 data at ASCO 2026 and has since started first-patient dosing in the Keytruda combination arm with MSD, with the company saying it plans to present additional data at global conferences such as ESMO in the second half of the year. ABF-101 resumed its U.S.
Phase 1 trial after the FDA lifted a clinical hold, with a goal of obtaining human safety and pharmacokinetic data by the first half of next year. Apta-16, which holds FDA orphan drug designation, is being prepared for domestic Phase 1 entry in the second half of the year.
Aptabio has said it is expanding licensing discussions through meetings with pharmaceutical companies and investors at global partnering events such as BIO USA 2026, though no specific licensing agreement or timeline has yet been disclosed.
Because Aptabio remains in a net-loss position even on a trailing four-quarter basis, earnings-based valuation metrics are difficult to apply meaningfully at this stage.
In terms of price-to-book, the shares trade at a notable premium to book value, which can be interpreted as reflecting anticipation of clinical readouts and potential licensing deals rather than realized earnings improvement.
The company has no dividend payment history, so dividend-yield comparisons are similarly not meaningful.
Looking at the multi-year trend, revenue has grown from a minimal base while the scale of operating losses, though volatile, appears to have eased somewhat after peaking in 2024; whether this trajectory continues will depend on upcoming clinical outcomes and financing conditions.
Ultimately, the current share price level appears to reflect market expectations tied to pipeline clinical progress and licensing potential far more than realized financial performance.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22
Global Phase 2 topline data for CI-AKI are due around late Q3 to early Q4, APX-343A has begun first-patient dosing in its Keytruda combination arm with further data expected at conferences like ESMO in H2, and Apta-16 is preparing for domestic Phase 1 entry in the same period.
Multiple pipeline inflection points are converging within a single year, and these data disclosures could serve as evidence in potential licensing discussions.
Setanaxib, which used the same NOX-inhibition mechanism, failed to demonstrate efficacy in a Phase 2 trial, yet its developer Calliditas Therapeutics was still acquired by Asahi Kasei in 2024 for roughly $1.1 billion. This has been cited as evidence of large pharma interest in the NOX-inhibition mechanism itself.
Aptabio positions its Pan-NOX approach, which targets all seven NOX isoenzymes, as a point of differentiation from setanaxib.
Total liabilities fell from KRW 23.24 billion in 2024 to KRW 12.84 billion in 2025, lowering the debt ratio from 42.9% to 27.2%. This reduction in leverage relative to equity could provide some financial cushion for funding further clinical expenses going forward.
From 2022 through 2025, revenue never exceeded roughly KRW 3.7 billion, while the operating loss ranged between KRW 9.5 billion and KRW 18.9 billion each year. In Q1 2026, the operating loss reached KRW 6.10 billion, the largest in the observed window, showing that loss expansion can recur. Revenue growth has consistently failed to keep pace with the scale of losses.
Operating cash flow was negative every year from 2022 through 2025, with 2025 showing the largest outflow in the window at KRW -15.28 billion. As a result, shareholders' equity fell from KRW 52.37 billion in 2022 to KRW 47.18 billion in 2025. Continued cash burn without offsetting revenue could increase the need for further financing.
The company has stated it has engaged in licensing discussions at numerous global partnering events over several years, but no specific agreement or upfront payment has yet been disclosed.
Given that the competing compound setanaxib failed to demonstrate efficacy in its own Phase 2 trial, the possibility that isuzinaxib's topline data could fall short of expectations cannot be ruled out.
Multiple pipelines—CI-AKI Phase 2, DKD Phase 2b, and the APX-343A combination trial—are simultaneously entering data-validation stages.
A competing compound using the same mechanism has previously failed to demonstrate efficacy in its own Phase 2 trial, so a disappointing topline result could lead to a reassessment of pipeline value and delays in licensing negotiations.
With operating cash flow negative for four consecutive years and equity being gradually eroded, additional financing may be needed to fund future clinical costs. Depending on the method of any future capital raise, existing shareholders should also consider the possibility of dilution.
Even in an unapproved-therapy area like CI-AKI, competing candidates using different mechanisms could emerge, and even a successful trial would still require additional regulatory steps and time before commercialization. Pursuing multiple pipelines in parallel could also pose risks in terms of resource-allocation efficiency.
Check whether and how the global Phase 2 topline data for isuzinaxib in CI-AKI are disclosed.
Check whether domestic patient enrollment for the DKD Phase 2b trial is completed and whether Apta-16 enters domestic Phase 1.
Check whether additional data from the APX-343A Keytruda combination trial are disclosed.
Check whether Q3 2026 earnings show continuity with the Q2 net income swing, and how revenue and operating loss trends evolve.
Aptabio is at a point where multiple pipelines—isuzinaxib for CI-AKI and DKD, and APX-343A for immuno-oncology in combination with MSD's Keytruda—are simultaneously entering clinical data-validation stages in the second half of 2026.
However, confirmed financial data show revenue remains minimal, operating losses have continued every year since 2022, and operating cash flow has been negative for four consecutive years, gradually eroding shareholders' equity.
The swing to positive net income in Q2 2026 is notable, but it occurred alongside a continuing operating loss and should not be read as an immediate sign of improved core profitability.
While a competing compound using the same NOX-inhibition mechanism was acquired by a major pharmaceutical company, another competitor using the same mechanism previously failed to demonstrate efficacy in its own Phase 2 trial, leaving considerable uncertainty around clinical outcomes.
Ultimately, the path forward will depend heavily on the outcomes of the multiple clinical data disclosures scheduled for the second half of the year and any resulting progress in licensing discussions.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.